Assess Common Surrogate Endpoints in Lymphoma using a Multistate Model

Abstract

Proportion of PD@24m or CR@30m are considered surrogate endpoints for OS in lymphoma. I provide OS predictions conditional on patient’s status at 24/30m based on a multistate model applied to one of the Gayzva P3 trials and discuss the advantage of multistate models over alternatives.

Date
Event
Roche Global Biostatistics Conference (contributed talk)
Location
Madrid, Spain